Skip to main content

Month: January 2026

Sachem Capital Corp. Announces Tax Reporting Information

BRANFORD, Conn., Jan. 29, 2026 (GLOBE NEWSWIRE) — Sachem Capital Corp. (NYSE American: SACH) announced today the tax treatment for the Company’s distributions on its common stock (CUSIP: 78590A109) and preferred stock (CUSIP: 78590A505) paid with respect to the calendar year ended December 31, 2025: COMMON STOCK TAX INFORMATION      Box 1a Box 1b Box 2a Box 3 Box 5               Record Date Payable Date Rate PerShare OrdinaryDividends PerShare QualifiedDividends PerShare Total CapitalGain PerShare NondividendDistributionPer Share Section 199ADividends PerShare3/17/2025 3/31/2025 $0.050000 $0.012362 $0.000000 $0.010840 $0.026798 $0.0123626/16/2025 6/30/2025 $0.050000 $0.012362 $0.000000 $0.010840 $0.026798 $0.0123629/15/2025 9/30/2025 $0.050000 $0.012362 $0.000000 $0.010840 $0.026798 $0.01236212/15/2025 12/30/2025 $0.050000 $0.012362 $0.000000 $0.010840 $0.026798 $0.012362  Total $0.200000 $0.049448 $0.000000 $0.043360 $0.107194 $0.049448 PREFERRED...

Continue reading

Skye Bioscience Highlights Attributes of its Peripherally-restricted CB1 Inhibitor Antibody at Keystone Obesity Conference

SAN DIEGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”) a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today presented a poster titled “Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet-Induced Obesity (DIO) Mouse Model” at Keystone’s conference, Obesity Therapeutics: Unlocking Benefits and Minimizing Side Effects. Skye’s presentation addressed the following questions regarding the ability of its peripherally-restricted CB1-inhibitor antibody:Can nimacimab enhance optimal and suboptimal doses of incretin agonists? How durable is nimacimab’s effect on weight loss after treatment discontinuation? Can...

Continue reading

Chicago Atlantic Real Estate Finance Announces Tax Reporting Information for 2025 Distributions

CHICAGO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Chicago Atlantic Real Estate Finance, Inc. (NASDAQ: REFI) (“Chicago Atlantic” or the “Company”), a commercial mortgage real estate investment trust, today announced year-end tax reporting information for its 2025 distributions. Stockholders are urged to consult with their personal tax advisors as to their specific tax treatment. Chicago Atlantic Real Estate Finance, Inc.CUSIP: 167239102Ticker: NASDAQ: REFIRecord Date Payment Date Cash Distribution (per share) Dividend (1) Ordinary Dividend(per share) Qualified Dividends(per share) Section 199A Dividends(per share)(2)3/31/2025 4/15/2025 $0.47 $0.47 $0.47 $0.00 $0.476/30/2025 7/15/2025 $0.47 $0.47 $0.47 $0.00 $0.479/30/2025 10/15/2025 $0.47 $0.47 $0.47 $0.00 $0.4712/31/2025 1/15/2026 $0.47 $0.47 $0.47 $0.00 $0.47 Pursuant...

Continue reading

Valley National Bancorp Reports Fourth Quarter 2025 Results

NEW YORK, Jan. 29, 2026 (GLOBE NEWSWIRE) — Valley National Bancorp (NASDAQ:VLY), the holding company for Valley National Bank, today reported net income for the fourth quarter 2025 of $195.4 million, or $0.33 per diluted common share, as compared to the third quarter 2025 net income of $163.4 million, or $0.28 per diluted common share, and net income of $115.7 million, or $0.20 per diluted common share, for the fourth quarter 2024. Excluding all non-core income and charges, our adjusted net income (a non-GAAP measure) was $180.2 million, or $0.31 per diluted common share, for the fourth quarter 2025, $164.1 million, or $0.28 per diluted common share, for the third quarter 2025, and $75.7 million, or $0.13 per diluted common share, for the fourth quarter 2024. See further details below, including a reconciliation of our adjusted...

Continue reading

ConnectOne Bancorp, Inc. Reports Fourth Quarter and Full-Year 2025 Results

Net Interest Margin Widens By 16 Basis PointsPerformance Metrics Gain MomentumBranch Rationalization to Result In 5 ClosuresCredit Trends Remain SolidDeclares Common and Preferred Dividends ENGLEWOOD CLIFFS, N.J., Jan. 29, 2026 (GLOBE NEWSWIRE) — ConnectOne Bancorp, Inc. (Nasdaq: CNOB) (the “Company” or “ConnectOne”), parent company of ConnectOne Bank (the “Bank”), today reported net income available to common stockholders of $38.0 million for the fourth quarter of 2025 compared with $39.5 million for the third quarter of 2025 and $18.9 million for the fourth quarter of 2024.  Diluted earnings per share were $0.75 for the fourth quarter of 2025 compared with $0.78 for the third quarter of 2025 and $0.49 for the fourth quarter of 2024.  Full-year 2025 net income available to common stockholders was $74.4 million, compared to $67.8...

Continue reading

Talisker Reaches Major Safety Milestone Achieving One Year Operations Anniversary LTI Free at the Bralorne Gold Project

TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Talisker Resources Ltd. (“Talisker” or the “Company”) (TSX: TSK, OTCQB: TSKFF) is pleased to announce that it has reached a major workplace milestone – one year of operations without a lost time incident at the Bralorne Gold Project (“Bralorne”). Mining services at the Mustang Mine commenced in January 2025 with Thyssen Mining Construction of Canada (“Thyssen”) undertaking mobilization, construction development followed by underground mining. Thyssen is a well-established mining contractor known for its proven track record of delivering high-quality, efficient mining services. Richard Murrell, General Manager, Bralorne stated, “Every person at Thyssen and Bralorne has contributed to this accomplishment by working hard and working safely over this past year. Our “One Bralorne Team” has shown...

Continue reading

Coastal Financial Corporation Announces Fourth Quarter 2025 Results

EVERETT, Wash., Jan. 29, 2026 (GLOBE NEWSWIRE) — Coastal Financial Corporation (Nasdaq: CCB) (the “Company”, “Coastal”, “we”, “our”, or “us”), the holding company for Coastal Community Bank (the “Bank”), through which it operates a community-focused bank segment (“community bank”) with an industry leading banking as a service (“BaaS”) segment (“CCBX”), today reported unaudited financial results for the quarter ended December 31, 2025, including net income of $12.6 million, or $0.82 per diluted common share, compared to $13.6 million, or $0.88 per diluted common share, for the three months ended September 30, 2025 and $13.4 million, or $0.94 per diluted common share, for the three months ended December 31, 2024, and $47.0 million, or $3.06 per diluted...

Continue reading

Nobel Closes Non-Brokered Private Placement Offering

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. TORONTO, Jan. 29, 2026 (GLOBE NEWSWIRE) — Nobel Resources Corp. (TSX–V: NBLC; OTCPK: NBTRF) (the “Company” or “Nobel”) announces that it has closed, on a fully-subscribed basis, its previously announced non-brokered private placement offering of 4,166,667 units (each a “Unit”) at a price of $0.06 per Unit for gross proceeds of $250,000 (the “Offering”).    Each Unit consists of one common share of the Company (each, a “Share”) and one-half of one common share purchase warrant (each whole warrant, a “Warrant”). Each Warrant entitles the holder to purchase one Share at a price of $0.075 until January 29, 2028. The securities issued pursuant to the Offering...

Continue reading

Kymera Therapeutics Announces First Patient Dosed in BREADTH Phase 2b Asthma Clinical Trial of KT-621, a First-in-Class, Oral STAT6 Degrader

Data from the BREADTH Phase 2b asthma trial is expected to be reported in late-2027 Data from the ongoing parallel BROADEN2 Phase 2b atopic dermatitis trial is expected to be reported by mid-2027 WATERTOWN, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that it recently initiated dosing in its BREADTH Phase 2b clinical trial evaluating KT-621, an oral, highly selective, potent degrader of STAT6, in patients with moderate to severe eosinophilic asthma. The Company expects to report data from the BREADTH trial in late-2027. “Untreated asthma can result in long-term medical complications. We continue to hear from physicians and patients that new treatment...

Continue reading

New Jersey orders additional 375 Xcelsior® clean-diesel buses from New Flyer

ST. CLOUD, Minn., Jan. 29, 2026 (GLOBE NEWSWIRE) — (TSX: NFI, OTC: NFYEF, TSX: NFI.DB) NFI Group Inc. (NFI), a leader in bus and coach mobility solutions, and subsidiary New Flyer of America Inc. (New Flyer), has received an additional order from New Jersey Transit Corporation (NJ TRANSIT) for 375 Xcelsior® 40-foot, clean-diesel transit buses. This order is part of a larger, previously announced multi-phase fleet replacement program, with orders placed in the third and fourth quarters of 2025. The original contract, awarded in the first quarter of 2024, included a base order of 550 Xcelsior 40-foot, clean-diesel transit buses to be delivered in three distinct lots, along with options for an additional 750 units. With this newly announced order, NJ TRANSIT has now completed the full base order of 550 buses, leaving all 750 option...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.